Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Walgreens Is The Worst Dow Stock Now, Will 2020 Be Different?

By Zacks Investment ResearchStock MarketsDec 15, 2019 08:48PM ET
www.investing.com/analysis/walgreens-is-the-worst-dow-stock-now-will-2020-be-different-200492775
Walgreens Is The Worst Dow Stock Now, Will 2020 Be Different?
By Zacks Investment Research   |  Dec 15, 2019 08:48PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

The healthcare space has not been among the best Dow Jones performers this year, thanks to the lingering U.S.-China trade dispute and fears of regulatory hindrances, among other factors. Among Dow stocks, drug retailor Walgreens Boots Alliance (NASDAQ:WBA) has been the worst performer.

Year to date, the stock has lost 15.3%, compared with the Dow Jones Index’s 20.61% rise.

2019 Hasn’t Been Kind

Walgreens has had a dismal stretch this year owing to a number of factors including rising drug costs and the threat of the entry of non-MedTech stalwarts like Amazon (NASDAQ:AMZN) , JP Morgan (NYSE:JPM) and Berkshire Hathaway (NYSE:BRKa) into the healthcare space.

Let us delve deeper.

Drug Cost Inflation:Going by an article in CBS News, more than 3,400 prescription drugs’ prices have been hiked in the first six months of 2019, showing an increase of 17% from a year earlier. This is inducing patients to replace prescription medicines with low-cost generic drugs. This has largely affected the business of the likes of Walgreens.

Healthcare Foray of Market Stalwarts: Shares of Walgreens have also been declining since non-healthcare leaders started floating major healthcare ventures. The price competition for Walgreens Boots has escalated with the emerging online peers eating into its pharmacy customers. Apart from Amazon, Walgreens has been facing immense competitive pressure from the likes of Walmart (NYSE:WMT) , which has been capturing market share in the profitable household and beauty categories. The presence of companies like Costco (NASDAQ:COST) and dollar store chains like Dollar General (NYSE:DG) , which are currently offering the same products as Walgreens across both online and physical stores at much cheaper rates, is also a bother.

Other Adverse Factors: Walgreens has also been hit by a FDA crackdown with regard to its sale of tobacco and e-cigarettes, especially to teenagers, this year. Brexit has been posing tough challenge to Walgreens as sales at its Boots UK stores declined due to the worsening of the consumer scenario in the U.K.

Sell-off News

Walgreens’ dismal performance has probably compelled it to consider a sell-off. A Nov 11 Bloomberg news stated about a potential deal citing some undisclosed source, which claimed that private equity firm KKR & Co. has formally forwarded a takeover offer to Walgreens Boots for $70 billion.

Investors had taken this news positively, as was evident from the 6% share price hike over the next two days. However, after the initial surge, the stock retraced after analysts raised doubt over the feasibility of such a massive deal.

Is There a Rebound in the Cards?

Walgreens, with a massive market cap of $51.51 billion, has been leaving no stones unturned. The company recently inked a number of agreements to diversify its product offerings and strengthen its retail pharmacy business.

While the company’s major peer CVS Health (NYSE:CVS) has adopted the growth-by-acquisition policy to defy all odds (through vertical integration by acquiring health insurance giant Aetna (NYSE:AET)), Walgreens is currently focusing on its front-end stores expansion and has announced partnerships with the likes of Kroger (NYSE:KR) and FedEx (NYSE:FDX). The FedEx alliance is aimed at offering convenient access to FedEx drop-off and pickup services at several of Walgreens locations across the nation. The Kroger alliance, in the meanwhile, is expected to boost the company’s supply-chain efficiency.

Further, the intensifying competition in the U.S. retail drugstore market has compelled Walgreens to diversify its product offerings. In line with this, investors are currently looking forward to its tie up with Alphabet’s life sciences and healthcare segment Verily on multiple projects pertaining to chronic ailment.

Walgreens is also progressing well with its collaboration with LabCorp. The company is planning to open at least 600 LabCorp patient centers across the United States, thereby offering diagnostic lab testing services in the community. During the fourth quarter, the company had opened 21 centers, taking the total to 58.

In a bid to ensure availability of specialty brand drugs, Walgreens tied up with Express Scripts (NASDAQ:ESRX) and plans to expand their existing group purchasing efforts. Since biosimilars have the potential to lower production costs, the move is considered a prudent and timely one.

We believe such measures will help straighten things out for the company in 2020, to a certain extent.

Further, according to a Dec 12 CNN.com news, the House Democrats passed a crucial bill to cut down prescription drug price in the United States. The bill, titled the Elijah E. Cummings Lower Drug Costs Now Act, would allow the Health & Human Services secretary to set, through an annual negotiation, the best prices for at least 50 costly branded prescription drugs and up to 250 medications, including insulin. Prices would be limited at 1.2 times their cost in certain other first world nations. If this drug-price cap bill finally gets implemented, Walgreens is sure to gain.

This Zacks Rank #3 (Hold) currently has a favorable price to earnings ratio (forward 12 months) of 9.69 as compared with the S&P 500 market’s 18.28 and the broader industry’s 10.16. The company also has favorable price to sales (forward 12 months) ratio of 0.36 compared with the S&P 500 market’s 3.33.

Bottom Line

In a market, where legal regulatory challenges and reimbursement pressure are historically altering the trend, it will be interesting to see how Walgreens deals with the odds and delivers the promised long-term earnings growth of 6.8%.

Zacks Top 10 Stocks for 2020

In addition to the stocks discussed above, would you like to know about our 10 top tickers for the entirety of 2020?

These 10 are painstakingly hand-picked from over 4,000 companies covered by the Zacks Rank. They are our primary picks to buy and hold.

Start Your Access to the New Zacks Top 10 Stocks >>



JPMorgan Chase & Co. (JPM): Free Stock Analysis Report

Amazon.com, Inc. (AMZN): Free Stock Analysis Report

Costco Wholesale Corporation (COST): Free Stock Analysis Report

Walmart Inc. (WMT): Free Stock Analysis Report

Dollar General Corporation (DG): Free Stock Analysis Report

CVS Health Corporation (CVS): Free Stock Analysis Report

Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report

Original post

Zacks Investment Research
Walgreens Is The Worst Dow Stock Now, Will 2020 Be Different?
 

Related Articles

Craig Erlam
Earnings Eyed For Next Boost By Craig Erlam - Oct 20, 2021

It’s been a day of small moves in equity markets, with Europe ending the day broadly flat and the U.S. marginally higher. Focus has very much shifted to earnings season as...

Walgreens Is The Worst Dow Stock Now, Will 2020 Be Different?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email